What is Nectar?
Nectar Allergy & Asthma focuses on delivering personalized care for individuals managing allergies, asthma, and eczema. The company offers a range of services, including both in-person and online testing, alongside customized treatment plans and immunotherapy options. Nectar aims to enhance the quality of life for its clients, encompassing both adults and children, through flexible care models and a strong emphasis on patient education. Operating out of New York City, Nectar accepts most major insurance plans and facilitates convenient appointment scheduling, positioning itself as a key player in accessible respiratory and allergic condition management.
How much funding has Nectar raised?
Nectar has raised a total of $16.5M across 1 funding round:
Series A
$16.5M
Series A (2022): $16.5M with participation from The Obvious, Harmony Partners, and Juxtapose
Key Investors in Nectar
The Obvious
The Obvious Corp is a creative and design firm specializing in transforming client ideas into compelling marketing and communications materials across various formats and channels, including strategic design, copywriting, and illustration.
Harmony Partners
Harmony Partners is a venture capital firm with over 30 years of experience, focusing on providing flexible, entrepreneur-friendly financing to help bold entrepreneurs scale their innovative products, having invested over $1.5 billion in more than 125 companies.
Juxtapose
Juxtapose is an inception-stage investment firm founded in 2015, dedicated to building industry-transforming businesses from the ground up, partnering with experienced operators to found and scale category-defining technology companies.
What's next for Nectar?
The recent major strategic investment signals a pivotal growth phase for Nectar. This capital infusion is expected to fuel the expansion of its service offerings, potentially enhancing its technological capabilities for remote patient monitoring and expanding its reach to new markets. The company's focus on personalized treatment plans and patient education, combined with flexible care options, positions it for continued success in addressing the growing demand for specialized allergy and asthma care. Future developments may include further integration of telehealth services and strategic partnerships to broaden its impact.
See full Nectar company page
